TABLE 3.
Subject | Dose (mg) | OPT-80
|
OP-1118
|
Total % of dose | ||
---|---|---|---|---|---|---|
Recovery (mg) | % of dose | Recovery (mg) | % of dose | |||
009 | 200 | 63.25 | 31.63 | 249.09 | 124.55 | 156.17 |
010 | 200 | 49.70 | 24.85 | 203.30 | 101.65 | 126.50 |
011 | 200 | 45.31 | 22.66 | 115.47 | 57.74 | 80.39 |
013 | 200 | 90.83 | 45.42 | 198.65 | 99.33 | 144.74 |
014 | 200 | 55.11 | 27.56 | 125.80 | 62.90 | 90.46 |
016 | 200 | 54.02 | 27.01 | 201.42 | 100.71 | 127.72 |
001 | 300 | 36.47 | 18.24 | 62.33 | 31.17 | 49.40 |
002 | 300 | 86.76 | 43.38 | 146.06 | 73.03 | 116.41 |
003 | 300 | 47.97 | 23.99 | 161.50 | 80.75 | 104.74 |
005 | 300 | 39.10 | 19.55 | 34.73 | 17.37 | 36.92 |
006 | 300 | 148.30 | 74.15 | 221.63 | 110.82 | 184.97 |
008 | 300 | 123.52 | 61.76 | 237.76 | 118.88 | 180.64 |
Mean (SD) | 35.01 (17.72) | 81.57 (34.15) | 116.59 (47.05) |
Data are not presented for the 100- and 450-mg dose groups, who completed the study as outpatients.